“…In this context, the search for new antibiotics presenting new modes of action to fight against resistant bacteria is becoming a pressing global need. In 2006, (−)-platensimycin (PTM), a meroditerpenoid from Streptomyces platensis , was isolated by Merck researchers. , Its activity has been tested against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant enterococci (VRE) among others. , Additionally, this substance possesses a unique mode of action as a suppressor of β-ketoacyl-(acyl-carrier protein) synthase II (FabF) engaged in the mechanism of fatty acid biosynthesis. , This unique mode of action, its challenging structural and functional architecture, has attracted the attention of many synthetic chemists, and consequently, a number of synthetic strategies have been developed to complete the synthesis of PTM and analogues. − Furthermore, a fermentation process for producing PTM from S. platensis SB12026 was described …”